In addition, given that GRPR antagonists turned out to be more resistant to degrading proteases compared with their agonist counterparts, the shift toward antagonist-based radioligands led to the development of efficient agents, primarily for the visualization and treatment of prostate cancer [11,12]. The gene discussed is GRPR; the disease is prostate cancer.